IVDs to detect SARS-CoV-2 nucleic acid that have US FDA Emergency Use Authorization are eligiblefor an abridged assessment pathway. For these applications, we accept the submission prepared forthe FDA. Note however that any additional requirements outlined in the WHO instructionsdocument must supplement the submission and the entire dossier will be assessed. We do notabridge any other national regulatory authority approvals for NAT assays (such as CE-marking,Chinese NMPA, ANVISA, Korea MFDS), nor any other types of IVDs.
